GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Sopharma AD-Sofia (FRA:3JR) » Definitions » Return-on-Tangible-Asset

Sopharma AD-Sofia (FRA:3JR) Return-on-Tangible-Asset : 5.13% (As of Dec. 2023)


View and export this data going back to 2010. Start your Free Trial

What is Sopharma AD-Sofia Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Sopharma AD-Sofia's annualized Net Income for the quarter that ended in Dec. 2023 was €37.8 Mil. Sopharma AD-Sofia's average total tangible assets for the quarter that ended in Dec. 2023 was €737.2 Mil. Therefore, Sopharma AD-Sofia's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2023 was 5.13%.

The historical rank and industry rank for Sopharma AD-Sofia's Return-on-Tangible-Asset or its related term are showing as below:

FRA:3JR' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 2.61   Med: 5.38   Max: 8.52
Current: 7.26

During the past 13 years, Sopharma AD-Sofia's highest Return-on-Tangible-Asset was 8.52%. The lowest was 2.61%. And the median was 5.38%.

FRA:3JR's Return-on-Tangible-Asset is ranked better than
84.85% of 99 companies
in the Medical Distribution industry
Industry Median: 2.48 vs FRA:3JR: 7.26

Sopharma AD-Sofia Return-on-Tangible-Asset Historical Data

The historical data trend for Sopharma AD-Sofia's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sopharma AD-Sofia Return-on-Tangible-Asset Chart

Sopharma AD-Sofia Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.52 2.61 7.76 6.08 7.23

Sopharma AD-Sofia Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.08 10.47 9.75 4.25 5.13

Competitive Comparison of Sopharma AD-Sofia's Return-on-Tangible-Asset

For the Medical Distribution subindustry, Sopharma AD-Sofia's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sopharma AD-Sofia's Return-on-Tangible-Asset Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Sopharma AD-Sofia's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Sopharma AD-Sofia's Return-on-Tangible-Asset falls into.



Sopharma AD-Sofia Return-on-Tangible-Asset Calculation

Sopharma AD-Sofia's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=49.765/( (623.41+753.344)/ 2 )
=49.765/688.377
=7.23 %

Sopharma AD-Sofia's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=37.824/( (721.091+753.344)/ 2 )
=37.824/737.2175
=5.13 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Dec. 2023) net income data.


Sopharma AD-Sofia  (FRA:3JR) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Sopharma AD-Sofia Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Sopharma AD-Sofia's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Sopharma AD-Sofia (FRA:3JR) Business Description

Traded in Other Exchanges
Address
5 Lachezar Stanchev Street, Sopharma Business Towers, Building A, Floor 11, Sofia, BGR, 1756
Sopharma AD-Sofia is a company engaged in the production of pharmaceutical products. Its principal activities include the production and trade of medicinal substances and finished drug forms; and research and development as well as engineering and implementation activities in the field of medicinal products. It is also focused on the distribution of pharmaceuticals like medical supplies, sanitary materials, vitamins, food supplements, and cosmetics. The company's segments are organized based on the production of finished products which include Tablet dosage forms, Ampoule dosage forms, Medical products, Other forms, and Other revenue. Geographically company operates in Bulgaria and internationally.

Sopharma AD-Sofia (FRA:3JR) Headlines

No Headlines